Background Pulmonary fibrosis (PF) caused by interstitial lung diseases (ILDs) affects up to 0.1% of the global population. There is growing global interest in PF, evident from a nearly threefold ...

Dr E Hnizdo, National Institute for Occupational Safety and Health, 1095 Willowdale Road, MS PB 163, Morgantown, WV 26505, USA BACKGROUND A study was undertaken to establish the chronic effect of ...

Introduction There is an unmet need for a validated qualitative and quantitative tool to assess environmental exposures in patients with interstitial lung disease (ILD). This study aimed to develop ...

Introduction Smoked tobacco is a leading risk factor for cardiopulmonary disease. Pipe and cigar use remains common among US adults, yet its risks remain insufficiently understood. Conclusion Pipe and ...

Asthma is a common lung disease and outcomes in the UK are among the worst in Europe. The overuse of short-acting beta agonist and underuse of anti-inflammatory, inhaled corticosteroid-containing ...

Correspondence to Dr Anna Hansell, UK Small Area Health Statistics Unit, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London W2 1PG, UK; ...

4 School of Public Health, University of Alberta, Edmonton, Alberta, Canada Background A COPD discharge bundle is a set of evidence-based practices aimed at improving patient outcomes after discharge ...

Correspondence to Dr Juhee Cho, Center for Clinical Epidemiology, Samsung Medical Center, Seoul 06351, South Korea; jcho{at}skku.edu There has been limited evidence for the association between chronic ...

1 Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA 2 Division of Pulmonary, Allergy and Critical Care Medicine, University of ...

Seven patients exposed to the inhalation of synthetic fibres presented with various bronchopulmonary diseases, such as asthma, extrinsic allergic alveolitis, chronic bronchitis with bronchiectasis, ...

Background The Quality of Life-Bronchiectasis (QOL-B), a self-administered, patient-reported outcome measure assessing symptoms, functioning and health-related quality of life for patients with ...

Background Conventional measures to evaluate COPD may fail to capture systemic problems, particularly musculoskeletal weakness and cardiovascular disease. Identifying these manifestations and ...